ADvantage logo.png
ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer
October 02, 2023 10:43 ET | Advantage Therapeutics Inc.
ADvantage Therapeutics appoints Dr. Carmela Abraham as Chief Science Officer
ADvantage logo.png
ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia
June 20, 2023 09:00 ET | Advantage Therapeutics Inc.
MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s...
ADvantage logo.png
MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease
April 05, 2023 08:35 ET | Advantage Therapeutics Inc.
MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...